Auckland firm’s neon‑pink MDMA import sparks ‘feel‑good’ frenzy on the NZX

A shipment of neon‑pink capsules arrived at the Auckland port, prompting customs officers to wonder if they were ordering a new brand of gummy bears.

Instead, the brightly‑coloured parcels were earmarked for a local NZX‑listed firm that has decided the next big health‑trend is selling therapist‑approved MDMA to the nation’s most stressed‑out kiwis.

The company’s press release – written in the style of a wellness blog – promises that the “mind‑expanding” substance will be carefully regulated, stored in climate‑controlled vaults, and only prescribed after a thorough meditation session.

Critics have raised eyebrows, noting that the same compound that fuels rave playlists is now being positioned as a prescription‑only remedy for PTSD, anxiety, and the occasional mid‑week slump.

Meanwhile, investors have started trading the stock as if it were a new super‑food, with analysts joking that the next earnings call will feature a ‘trip report’ section.

If the venture succeeds, the firm could become the world’s first publicly listed psychedelic pharmacy, proving that in New Zealand, even drug reform can be a share‑price story.